A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BRIM8
  • Sponsors Roche
  • Most Recent Events

    • 11 Sep 2017 According to a Roche media release, full data will be presented today at the European Society of Medical Oncology (ESMO) annual meeting 2017.
    • 11 Sep 2017 Primary endpoint (Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT) in patients with stage IIIC melanoma (cohort 2) has not been met.
    • 11 Sep 2017 Results published in a Roche media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top